Vanda Pharmaceuticals (VNDA) Net Income (2010 - 2026)
Vanda Pharmaceuticals (VNDA) reported Net Income of -$48.5 million for Q1 2026, down 64.52% on a YoY basis from -$136.8 million in Q1 2025, and up 65.63% sequentially from -$141.2 million in Q4 2025.
Vanda Pharmaceuticals (VNDA) Net Income (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 17 years of Net Income data on file, last reported at -$48.5 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income fell 64.52% year-over-year to -$48.5 million; the trailing twelve-month figure through Mar 2026 stood at -$239.5 million (down 441.44% YoY), and the FY2025 full-year result was -$220.5 million, down 1066.53% from the prior year.
- Net Income climbed to -$48.5 million in Q1 2026, from -$141.2 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $6.9 million in Q4 2022 to a low of -$141.2 million in Q4 2025.
- A 5-year average of -$16.4 million and a median of -$4.5 million in 2024 frame the typical range for Net Income.
- Across the five-year window, Net Income jumped 149.94% in 2023 and slumped 4000.73% in 2024, its largest moves.
- Tracing VNDA's Net Income over 5 years: stood at $6.9 million in 2022, then sank by 134.85% to -$2.4 million in 2023, then slumped by 103.93% to -$4.9 million in 2024, then plunged by 2795.55% to -$141.2 million in 2025, then jumped by 65.63% to -$48.5 million in 2026.
- Business Quant data shows VNDA's Net Income at -$48.5 million in Q1 2026, -$141.2 million in Q4 2025, and -$22.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Vanda Pharmaceuticals | 318.71 Mn | 116.40 Mn | 48.56 Mn | -48.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.52 Mn |
| Dec 31, 2025 | -141.19 Mn |
| Sep 30, 2025 | -22.59 Mn |
| Jun 30, 2025 | -27.19 Mn |
| Mar 31, 2025 | -29.49 Mn |
| Dec 31, 2024 | -4.88 Mn |
| Sep 30, 2024 | -5.34 Mn |
| Jun 30, 2024 | -4.52 Mn |
| Mar 31, 2024 | -4.15 Mn |
| Dec 31, 2023 | -2.39 Mn |
| Sep 30, 2023 | 137,000.00 |
| Jun 30, 2023 | 1.49 Mn |
| Mar 31, 2023 | 3.23 Mn |
| Dec 31, 2022 | 6.86 Mn |
| Sep 30, 2022 | 3.26 Mn |
| Jun 30, 2022 | 2.59 Mn |
| Mar 31, 2022 | -6.46 Mn |
| Dec 31, 2021 | 7.08 Mn |
| Sep 30, 2021 | 7.72 Mn |
| Jun 30, 2021 | 9.65 Mn |